Significantly more patients treated with Sotyktu achieved ACR and PASI response rates and had greater improvements in patient-reported quality of life compared with placebo at Week 16
Sotyktu was well-tolerated in comparison with placebo and apremilast, demonstrating safety consistent with its established clinical profile
https://finance.yahoo.com/news/bristol-myers-squibb-presents-breaking-140100544.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.